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Abstract
Upregulation of neuronal nicotinic acetylcholine receptors (AChRs) is a venerable result of 
chronic exposure to nicotine; but it is one of several consequences of pharmacological 
chaperoning by nicotine and by some other nicotinic ligands, especially agonists. Nicotinic ligands 
permeate through cell membranes, bind to immature AChR oligomers, elicit incompletely 
understood conformational reorganizations, increase the interaction between adjacent AChR 
subunits, and enhance the maturation process toward stable AChR pentamers. These changes and 
stabilizations in turn lead to increases in both anterograde and retrograde traffic within the early 
secretory pathway. In addition to the eventual upregulation of AChRs at the plasma membrane, 
other effects of pharmacological chaperoning include modifications to endoplasmic reticulum 
stress and to the unfolded protein response. Because these processes depend on pharmacological 
chaperoning within intracellular organelles, we group them as “inside-out pharmacology”. This 
term contrasts with the better-known, acute, “outside-in” effects of activating and desensitizing 
plasma membrane AChRs. We review current knowledge concerning the mechanisms and 
consequences of inside-out pharmacology.
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1. Introduction
In 1983, it was discovered that chronic exposure to nicotine leads to an increased binding of 
nicotine at neuronal nicotinic acetylcholine receptors (AChRs) (Breese et al., 1997; Mamede 
et al., 2007; Marks et al., 1983; Nashmi et al., 2007; Schwartz and Kellar, 1983). This 
phenomenon was soon summarized by the appropriate but mechanistically vague term, 
“upregulation”. Denotations and connotations of AChR upregulation have changed as the 
process has continued to be studied with advances in molecular and cellular biology, 
allowing applications of mechanistic understanding. Radioligand binding assays do continue 
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to show an increase in AChR number and a more selective increase in the number of high-
affinity nicotine binding sites (Bencherif et al., 1995; Benwell et al., 1988; Darsow et al., 
2005; Flores et al., 1992; Govind et al., 2012; Marks et al., 1983; Peng et al., 1994; Vallejo 
et al., 2005). We now understand that 3H-nicotine or 3H-epibatidine binding to AChRs, 
which reveals increased high-affinity binding, is only a partial description. Often, an 
increase in total binding, beyond increased cell surface binding, has been reported. 
Therefore, upregulation of AChRs involves an increase in AChR abundance in several 
organelles (endoplasmic reticulum [ER], Golgi, etc.) and is certainly not limited to the PM. 
More recently, optical measurements using AChRs tagged with fluorescent proteins have 
provided measurements of increased AChR number without relying on ligand binding 
(Henderson et al., 2014; Nashmi et al., 2007; Renda and Nashmi, 2012; Richards et al., 
2011; Srinivasan et al., 2011). Thus, upregulation is becoming understood as a change in 
AChR number, stoichiometry, and trafficking (Darsow et al., 2005; Kuryatov et al., 2005; 
Lester et al., 2009; Miwa et al., 2011; Nelson et al., 2003; Sallette et al., 2005). As noted in 
Section 4.3 below, at the PM, prolonged exposure to nicotine may also favor higher-affinity 
AChR conformations on the PM, which also fits some definitions of “upregulated” (Govind 
et al., 2009).
Upregulation of AChRs occurs in clonal cell lines, cultured neurons, in mice, and in humans 
(Lester et al., 2012; Miwa et al., 2011; Mukhin et al., 2008; Nashmi et al., 2007; Srinivasan 
et al., 2011). Upregulation of AChRs in humans has been detected by comparing 
[3H]nicotine binding to postmortem brains of smokers and non-smokers and in vivo by 
fMRI or PET imaging (Benwell et al., 1988; Breese et al., 1997; Brody et al., 2013; Brody et 
al., 2008; Brody et al., 2011; Brody et al., 2006; Cosgrove et al., 2009; Jasinska et al., 2013; 
Mamede et al., 2007; Perry et al., 1999; Staley et al., 2006; Wullner et al., 2008). Heavy 
smokers (>14 cigarettes/day) have 25%-330% more AChRs when compared to non-smokers 
(Mukhin et al., 2008). In rodents, pharmacologically relevant concentrations of nicotine, 
over 10 days, produce 34%-110% more AChRs (Henderson et al., 2014; Nashmi et al., 
2007). In both humans and rodents, upregulation following chronic nicotine is found in the 
brainstem, cerebellum, prefrontal cortex, and corpus callosum (Brody et al., 2013; Doura et 
al., 2008; Henderson et al., 2014; Jasinska et al., 2013; Marks et al., 1992; Mukhin et al., 
2008; Nashmi et al., 2007; Nguyen et al., 2003; Pauly et al., 1991). Given that upregulation 
occurs in many systems, it is likely that the cause(s) for upregulation is a process common to 
many cell types.
Yet, upregulation is also selective, as shown in more detail below. For instance, no 
upregulation has been detected in thalamus. There are region-specific or cell-specific 
parameters involved in upregulation (discussed further in section 2.5). In several brain 
regions, maintained nicotine administration produces half of the maximal upregulation of 
high sensitivity AChRs after just one day. Continued administration produces additional 
increases over one to several weeks (Marks et al., 1991; Pietila et al., 1998).
There are many suggestions about the mechanistic details of upregulation including: 
activation-based, desensitization-based, conformation-based, and turnover-based 
mechanisms. Recently, many studies have converged on the concept that nicotine acts inside 
cells to enhance a critical step(s) in the maturation process of AChRs (Henderson et al., 
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2014; Kuryatov et al., 2005; Sallette et al., 2005; Srinivasan et al., 2011). This intracellular 
enhancement process has been characterized as pharmacological chaperoning (Kuryatov et 
al., 2005; Lester et al., 2009), and it occurs at the nanomolar concentrations thought to 
persist in the brain for hours after a person smokes (50 – 200 nM) (Benowitz, 1990; 
Henningfield et al., 1990). Approximately such a mechanism was indeed suggested earlier 
(Bencherif et al., 1995). It is likely that upregulation of AChRs includes multiple 
contributions from these various suggested mechanisms.
Here, we discuss our current understanding of the upregulation of AChRs as a consequence 
of pharmacological chaperoning and maturational enhancement. This review is not a 
synopsis at upregulation in general, but a summation of pharmacological chaperoning of 
AChRs by nicotinic ligands. The process of pharmacological chaperoning is not unique to 
nicotine and occurs with many nicotinic ligands that readily permeate cell membranes. The 
events we describe are conceptualized under the perspective of ‘inside-out’ and ‘outside-in’ 
drug interactions. Outside-in pharmacology presents the classical view of drug-receptor 
pharmacology where drugs bind to receptors on the PM to exert an effect. Inside-out 
pharmacology presents a view where drugs exert their effects through events inside of the 
cell and not on the surface of the cell (Kuryatov et al., 2005; Lester et al., 2009; Nichols et 
al., 2014; Sallette et al., 2005). Beginning in the late 90’s, evidence began to emerge as to 
the intracellular actions of nicotine and nicotinic ligands. In 1995, Bencherif et al., 
(Bencherif et al., 1995) hypothesized that there existed an additional, reserve pool of AChRs 
that were undetectable by [3H]-nicotine binding; but are converted to ‘upregulated’, high-
affinity AChRs following chronic nicotine exposure. It was suggested that this reserve 
population was of predominant intracellular localization. In 1998, Whiteaker et al., 
(Whiteaker et al., 1998) documented that roughly 85% of the high-affinity binding occurred 
intracellularly. Moreover, that study showed that in cases of nicotine-induced upregulation 
of PM AChRs, there is a greater increase of intracellular AChRs. This work also provided 
the early observations of nicotine and nicotinic ligands permeating membranes (Whiteaker 
et al., 1998). In 2005, two reports were made of observations inside the cell involving 
nicotine’s ability to act as a maturational enhancer (Sallette et al., 2005) and/or 
pharmacological chaperone (Kuryatov et al., 2005). In 2011, it was observed that nicotine’s 
effect on upregulation manipulates events associated with ER export (Richards et al., 2011; 
Srinivasan et al., 2011). These findings over time have led to a proposed inside-out 
mechanism upregulation by nicotinic ligands. The inside-out actions of nicotinic ligands 
include, but are presumably not limited to: 1) pharmacological chaperoning, 2) 
pharmacological matchmaking, and 3) Golgi-ER cycling.
In this review, we discuss the role that inside-out pharmacology of nicotinic ligands play on 
AChRs and how these actions relate to nicotine addiction and potential neuroprotection 
against Parkinson’s disease. Indeed, inside-out effects may predominate more widely in 
neuropharmacology, for instance in the therapeutic effects of antidepressant and 
antipsychotic drugs (Lester et al., 2012).
Despite the generality of upregulation with regard to the cellular assay system, this review 
shows that upregulation is also selective at every level examined. This selectivity extends to 
the brain region examined, the neuronal cell type within region, the somatodendritic vs. 
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axon terminal region of the neuron, the subunits contributing to the AChR, the detailed 
stoichiometry of α vs β subunits within the AChR pentamer, and possibly auxiliary proteins 
that contribute to proteostasis and trafficking on the AChR.1
2. Upregulation of AChRs depends on AChR subtype
Neuronal AChRs are pentameric receptors. Neuronal AChRs can be composed of α (α2-α7) 
and β (β2-β4) AChR subunits (Chavez-Noriega et al., 1997; Kuryatov and Lindstrom, 2011). 
They assemble as homomers (α7) or heteromers (containing α and β AChR subunits). 
Muscle AChRs contain α1, β1, δ, and either γ or ε subunits. In the CNS, the primary AChRs 
are α7 and β2* (α4β2*, α6β2*, α4α6β2*) AChRs (*, IUPHAR nomenclature meaning 
“other subunits may be present”) (Lukas et al., 1999). α3* AChRs exist in the CNS but are 
not so prevalent as the α7 or α4* AChR subtypes. Instead, they are in high abundance in the 
peripheral nervous system. These various AChR subtypes exhibit a diverse range of 
sensitivities to nicotine and other nicotinic ligands (Albuquerque et al., 2009; Brown et al., 
2007; Chavez-Noriega et al., 1997; Jensen et al., 2005; Kuryatov and Lindstrom, 2011; 
Tapia et al., 2007). Likewise, the various AChR subtypes seem to be chaperoned differently 
by nicotine, leading to vastly different properties of upregulation (see section 5.7).
2.1 – Upregulation of α4β2 AChRs
Of all the subtypes, α4β2 AChRs are the most extensively characterized and have been 
shown to upregulate by low (≤100 nM) (Henderson et al., 2014; Peng et al., 1994; 
Srinivasan et al., 2011) and high concentrations (>1 μM) (Peng et al., 1994) of nicotine. 
α4β2 AChRs are assembled into two distinct stoichiometries: the high-sensitivity (HS) 
(α4)2(β2)3 and low-sensitivity (LS) (α4)3(β2)2 AChRs (Nelson et al., 2003; Tapia et al., 
2007). Interestingly, nicotine selectively upregulates the HS AChR stoichiometry 
(Henderson et al., 2014; Kuryatov et al., 2005; Nelson et al., 2003; Srinivasan et al., 2011) 
(discussed further below). The EC50 for nicotine-induced upregulation of α4β2 AChRs 
depends on the assay system but is usually tens to hundreds of nM (Peng et al., 1994), a 
pharmacologically relevant concentration, as the steady state plasma concentration of 
nicotine during repeated smoking is ~150 nM (Benowitz, 1990; Henningfield et al., 1990). 
In some cell lines, α4β2 AChRs reach maximal upregulation in 24-48 hours (Henderson et 
al., 2014; Srinivasan et al., 2011; Walsh et al., 2008). Other reports using cell lines show that 
the time course of nicotine-induced upregulation occurred over several days with maximal 
upregulation occurring in 3-14 days (Peng et al., 1994). These latter assays resemble in vivo 
concentrations where α4* AChR upregulation typically reaches maximal levels at 10-14 
days (Henderson et al., 2014; Marks et al., 1983; Marks et al., 2004; Matta et al., 2007; 
Nashmi et al., 2007). α4β2 AChR upregulation on the PM may be accompanied by a 
dramatic increase in the number of AChRs in the ER (Kuryatov et al., 2005; Srinivasan et 
al., 2011; Whiteaker et al., 1998). In some studies, the fractional increase in ER-resident 
α4β2 AChRs actually exceeds the fractional increases in α4β2 AChRs inserted on the PM 
1Non-standard abbreviations: ACh, acetylcholine; AChR, nicotinic acetylcholine receptor; DhβE, dihydro-β-erythroidine ; COPI, 
coat protein complex 1; COPII, coat protein complex II; DMPP, 1,1-dimethyl-4-phenylpiperazinium iodide; ER, endoplasmic 
reticulum; HS, high-sensitivity; LS, low-sensitivity; MCC, methylcarbamylcholine; NCA, non-competitive antagonist; PD, 
Parkinson’s disease, PM, plasma membrane; SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulata; TMA, 
tetramethylammonium; TG/TGN, trans-Golgi and trans-Golgi network; UPR, unfolded protein response; VTA, ventral tegmental area.
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(Srinivasan et al., 2011; Srinivasan et al., 2012). Others have found no marked increase in 
the number of ER resident AChRs following chronic nicotine (Sallette et al., 2005; Vallejo 
et al., 2005). In any case, there is never a decrease in ER-resident AChRs. The increase of 
α4β2 AChR density in the ER is accompanied by an increase in export from the ER via 
COPII and an increase of insertion on the PM (Richards et al., 2011; Srinivasan et al., 2011). 
In cell lines, the upregulation of α4β2 AChRs may also be associated with an increase in the 
stability on the PM (a reduced turnover rate) (see section 4.5 for additional details
2.2 – Upregulation of α6* AChRs
In comparison to α4* AChRs, α6* AChRs are found in more restricted cell types. The best-
characterized α6* AChR populations occur in catecholaminergic neurons of the mesolimbic 
and nigrostriatal regions (Henderson et al., 2014; Mackey et al., 2012; Quik and McIntosh, 
2006). Several major α6* AChR subtypes have been identified in midbrain and striatal 
regions, including: α6(non-α4)β2* and α4α6β2* AChRs (Champtiaux et al., 2003; 
Champtiaux et al., 2002; Marubio et al., 2003). Many studies in rodents suggest that α6β2* 
AChRs do not upregulate following chronic nicotine exposure (McCallum et al., 2006a; 
McCallum et al., 2006b; Moretti et al., 2010; Mugnaini et al., 2006; Perry et al., 2007). 
Despite this, there have been recent reports of upregulation with α6* AChRs following 
chronic nicotine treatment (Henderson et al., 2014; Perez et al., 2008; Tumkosit et al., 2006; 
Walsh et al., 2008). This occurs in all brain regions where α6* AChRs are found: the ventral 
tegmental area (VTA), substantia nigra pars compacta (SNc), superior colliculus, and medial 
habenula (Henderson et al., 2014). In partial resolution of this confusing picture, Perez et al., 
(2008) has shown that α6β2* AChRs that do not contain α4 AChR subunits (α6[non-α4]β2) 
are upregulated by nicotine, while α4α6β2* AChRs are not upregulated by nicotine.
Recent in vitro experiments show that the upregulation of α6β2β3 AChRs is accompanied 
by an increased rate of insertion of receptors into the PM (Henderson et al., 2014). The fold 
increase in insertion to the PM can roughly account for the fold increase in AChR density on 
the PM. Like α4β2 AChRs, α6β2* AChRs also exhibit an increase in export from the ER 
following chronic nicotine treatment (Henderson et al., 2014). Therefore it is possible that 
the upregulation of α6* AChRs is principally due to an increased insertion of new AChRs 
rather than a change in the stability or turnover of pre-existing AChRs at the PM. In our 
view, the mechanism of PM insertion is not influenced by nicotine. However, upregulation 
has increased the pool of intracellular pentameric AChRs awaiting contact with the insertion 
machinery. Furthermore, we (and others) have found that α6β2* AChRs are upregulated by 
nicotine and likely require co-assembly with β3 AChR subunits to be upregulated 
(Henderson et al., 2014; Tumkosit et al., 2006). α6β4* AChRs were found to upregulate 
following chronic nicotine treatment in the presence and absence of the β3 AChR subunit 
(Henderson et al., 2014).
2.3 – Upregulation of α3* AChRs
α3* AChRs are primarily assembled in the peripheral nervous system and play important 
roles in the autonomic nervous system. In the CNS, α3* AChRs are assembled in the 
thalamus, hypothalamus, locus coeruleus, and habenula (Fowler and Kenny, 2012; Jensen et 
al., 2005; Shih et al., 2014).
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α3β4* AChRs generally have been reported to not upregulate at nicotine concentrations 
pharmacologically relevant to the smoking brain (50-200 nM). They do undergo 
upregulation at concentrations of nicotine ≥10 μM (Mazzo et al., 2013; Peng et al., 1997). 
However, such nicotine concentrations may occur transiently in the airways during smoking 
(Benowitz et al., 1988). In vitro, α3β4 AChRs are less sensitive (by ~10-fold) to nicotine-
induced upregulation when compared to α3β2 AChRs (Walsh et al., 2008). Recently, it has 
been documented that nicotine produces a change in stoichiometry on α3β4 AChRs as it 
does on α4β2 AChRs: (α3)2(β4)3 AChR stoichiometry is preferred over (α3)3(β4)2 AChR 
stoichiometry following chronic treatment with nicotine (Mazzo et al., 2013).
Where upregulation of α3β4 AChRs has been observed, only a small proportion of 
upregulation occurs at the PM (~30% increase in surface AChRs) while most of the 
upregulated AChRs reside in intracellular organelles (~95% of the upregulated α3β4 AChRs 
are found in the ER) (Peng et al., 1997). This amount of surface AChR upregulation is small 
compared to α4* and α6* AChRs (~2-Fold increase in surface AChRs) (Henderson et al., 
2014; Srinivasan et al., 2011).
2.4 – Upregulation of α7* AChRs
α7 AChRs are another AChR subtype that is widely distributed in the brain. α7 AChRs are 
found in the spinal cord, amygdala, olfactory region, cortex, hippocampus, cerebellum, and 
hypothalamus (Jensen et al., 2005).
α7 AChRs are noted for their potential role in schizophrenia (Freedman et al., 2000) and 
lung carcinoma (Brown et al., 2013b). Of interest, the postmortem analysis of schizophrenic 
brains has found that α7 AChRs are decreased in the hippocampus, cortex, and thalamus (~ 
50%) when compared to non-schizophrenic brains (Freedman et al., 1995). Nicotine-induced 
upregulation of α7 AChRs had been detected in rodents using [125I]-α-bungarotoxin 
(Collins et al., 1990; Marks et al., 1983; Marks et al., 1986). In the case of humans, 
upregulation of α7 AChRs was detected postmortem; but only in very heavy smokers 
(Leonard et al., 2000). In cell lines, when upregulation of α7 AChRs is observed, it occurs at 
concentrations that are higher than the pharmacologically relevant range for moderate 
smokers (Peng et al., 1997). In many cases, when α7 AChR upregulation is observed, the 
increase is much less than observed for α6* and α4* AChRs (i.e., 33% increase (Peng et al., 
1997)).
There is evidence that α7 AChRs upregulate by a different mechanism than β2* and β4* 
AChRs (Peng et al., 1997). β2/4* AChRs do not require activation of surface AChRs to 
upregulate (discussed in section 4.1). α7 AChR upregulation has been shown to be 
attenuated by competitive AChR antagonists (Peng et al., 1997), suggesting that activation 
of α7 AChRs may be required for α7 AChR upregulation (Peng et al., 1997). Brown et al., 
(Brown et al., 2013a) contributed to these findings by reporting upregulation of α7 AChRs 
(along with an increase in mRNA levels) through recruitment of Sp1-GATA4 or Sp1-
GATA6 (Brown et al., 2013a). Although Brown et al., (Brown et al., 2013a) reports an 
increase in α7 mRNA, many report no increase in mRNA following chronic nicotine (Peng 
et al., 1997). Interestingly, this upregulation occurred at concentrations of nicotine that are 
pharmacologically relevant to human smokers (100 nM). The caveat to these findings by 
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Brown et al. is that the upregulation in vitro and in vivo were observed in model systems 
used to study carcinogenesis (SCC-L cell line and chorioallantoic membrane models (Brown 
et al., 2013a)). Other studies, which cannot be reviewed here, suggest that some α7 AChR 
signaling occurs via their uniquely high Ca2+ permeability, and this Ca2+ flux may also 
underlie the occasional observations of α7 AChR upregulation.
2.5. Cell-specific upregulation
In addition to AChR subtype being a factor of upregulation, there also appears to be region- 
and cell-specific features that influence AChR upregulation. We have shown that α4* 
AChRs upregulate robustly in midbrain GABAergic neurons of the substantia nigra pars 
reticulata (SNr), SNc and VTA (Nashmi et al., 2007). Despite this, there was no significant 
upregulation of α4* AChRs in dopaminergic neurons of the VTA and SNc. The same trend 
was found when electrophysiological assays were used to document functional upregulation 
of α4β2* AChRs in midbrain regions (Nashmi et al., 2007; Xiao et al., 2009). What is the 
mechanism regulating that α4β2 AChRs in GABAergic neurons upregulate and α4β2 
AChRs in dopaminergic neurons do not? It may be that different assemblies or 
stoichiometries of AChRs exist among GABAergic and dopaminergic neurons. In fact, 
GABAergic neurons in midbrain regions have been suggested to express α4α5β2 AChRs in 
addition to α4β2 AChRs (McClure-Begley et al., 2009). Dopaminergic neurons express 
many β2* AChRs (α4β2*, α4α6β2*, and α6(non-α4)β2*) (Champtiaux et al., 2003; 
Champtiaux et al., 2002; Gotti et al., 2005; Marubio et al., 2003). There is evidence that 
α4α5β2* and α4α6β2* AChRs do not upregulate (Moretti et al., 2010; Perez et al., 2008) 
and many reports show that α6(non-α4)β2* and α4β2* AChRs upregulate (Henderson et al., 
2014; Nashmi et al., 2007; Perez et al., 2008; Renda and Nashmi, 2012). It is possible that 
the upregulation observed in GABAergic neurons is primarily α4(non-α5)β2. The absence 
of α4β2 AChR upregulation in dopaminergic neurons (Nashmi et al., 2007) may suggest that 
the majority of α4* AChRs in midbrain dopaminergic neurons are α4α6β2 AChRs which do 
not upregulate (Perez et al., 2008). The remainder of AChRs in midbrain dopaminergic 
neurons may be α6(non-α4)β2 AChRs as we have detected α6* upregulation in midbrain 
dopaminergic neurons of the VTA and SNc (Henderson et al., 2014). Together, these 
observations may at least partially explain the cell-specific upregulation of α4β2* AChRs.
2.6. Differential exposure with nicotine influences upregulation
In the preceding section, we discussed observations of upregulation of GABAergic neurons 
of the VTA and SNr with no change in dopaminergic neurons of the VTA and SNc. 
Recently, it has been demonstrated that intermittent exposure to nicotine (one dose on 
alternate days) does evoke a transient (hours) functional upregulation of AChRs in VTA 
dopaminergic neurons (Baker et al., 2013). This work also documented that intermittent 
nicotine exposure produced no functional upregulation on VTA GABAergic neurons. 
Furthermore, Baker et al., showed that intermittent activation and upregulation of AChRs by 
nicotine played a major role in behavioral sensitization to nicotine. This is extremely 
interesting, because many beginning smokers intermittently consume cigarettes. This also 
provides another example of cell-specific or region-specific upregulation as Baker et al., 
documented upregulation of AChRs in VTA dopaminergic neurons; but no upregulation of 
AChRs in VTA GABAergic neurons or neurons in the nucleus accumbens (Baker et al., 
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2013). Baker et al. suggested that the transient upregulation in their experiments may 
involve α6β2* AChRs, rather than the α4β2* AChRs studied previously (Nashmi et al., 
2007).
3. Molecular, Cellular and circuit consequences of upregulation
3.1 – Transcriptional events accompanying upregulation
In this age of transcriptomics, readers often assume that upregulation of a protein results 
from gene activation. This is not the case for the effects of chronic nicotine on heteromeric 
AChRs.
There is agreement that mRNA levels of AChRs are not changed significantly following 
chronic nicotine exposure (Marks et al., 1992). Northern blot assays in cultured M10 cells 
revealed no change in the mRNA levels of AChRs following chronic nicotine treatment 
despite an increase in protein binding (Bencherif et al., 1995; Peng et al., 1994). Binding 
studies clearly show that despite the fact that there is no change in mRNA levels, protein 
levels of AChRs are increased following chronic nicotine treatment. Furthermore, even 
when experimenters inject fixed amounts of cRNA in Xenopus oocytes, nicotine-induced 
upregulation still occurs. More importantly, in brain the upregulation of AChRs does not 
appear to be accompanied by an increase in mRNA either (Marks et al., 1992; Pauly et al., 
1996).This suggests that upregulation is independent of transcriptional events and is likely to 
occur through post-transcriptional mechanisms (Albuquerque et al., 2009; Lester et al., 
2009; Miwa et al., 2011). Similar studies were conducted in mouse fibroblasts (Flores et al., 
1992; Marks et al., 1992) and further suggest that nicotine-induced upregulation occurs 
through a post-transcriptional mechanism. Exceptions were found for α7 AChRs by Lam et 
al., (Lam et al., 2007) and Brown et al., (Brown et al., 2013a) as both showed that chronic 
nicotine treatment increased mRNA levels of α7 AChRs (mentioned above).
Although mRNA levels have been found to remain unchanged following chronic nicotine, 
are new AChR subunits synthesized so that upregulation may occur? When the protein 
synthesis inhibitor cycloheximide was added with nicotine, α4β2 AChRs still upregulated 
~10-fold (Wang et al., 1998). This suggests that AChR upregulation does not require the 
synthesis of new protein as the existing pool of AChR subunits can be used for the enhanced 
stable assembly of pentamers.
3.2 – Functional and pharmacological products of upregulation
Nicotine-induced upregulation does not alter the “steady-state” affinity of nicotine on α4β2 
AChRs, as measured by assays that incubate ligands and membranes for 20 min (Peng et al., 
1994). While AChRs upregulate ~2.5 fold, the steady-state Kd of nicotine on untreated and 
nicotine treated cells was 3.8 ± 0.8 and 5.6 ± 1.0 nM, respectively (Peng et al., 1994). 
Although the affinity for nicotine on α4β2 AChRs is unchanged, upregulation is 
accompanied by a change in AChR sensitivity. That is, maintained nicotine exposure results 
in a selective increase in HS α4β2 AChRs (Kuryatov et al., 2005; Nelson et al., 2003; Tapia 
et al., 2007). The proportion of HS α4β2 AChRs on the PM increases at the expense of the 
proportion of LS α4β2 AChRs. As a result, sensitivity to agonist stimulation and 
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desensitization is increased following chronic treatment with nicotine as additional α4β2 
AChRs respond to lower concentrations of ACh and nicotinic agonists.
As mentioned (section 2.5), upregulation of α4* AChRs occurs in the GABAergic neurons 
of the VTA; but may not occur in the dopaminergic neurons which are inhibited by these 
same GABAergic neurons (Xiao et al., 2009). Selective upregulation of α4* in GABAergic 
neurons increases the baseline firing rate and the excitatory effect of nicotine in GABAergic 
neurons; but decreases the baseline firing rate and excitatory effect of nicotine in 
dopaminergic neurons (Nashmi and Lester, 2007; Xiao et al., 2009). This, in part, may be an 
explanation for tolerance to the chronic effects of nicotine (Nashmi et al., 2007).
Cognitive sensitization is apparent by many smokers’ accounts that they are able to think 
better when they smoke. Likewise, rodents exposed to nicotine exhibit improved spatial 
working memory (Levin et al., 1996; Levin et al., 1990) and improved contextual fear 
conditioning (Davis et al., 2005a; Davis et al., 2005b). These cognitive enhancements of 
nicotine exposure may be explained by α4* AChR upregulation in the hippocampus. 
Chronic nicotine increases α4* AChRs on glutamatergic axons of the medial perforant path 
(Nashmi et al., 2007). As a result, nicotine exposure lowers the threshold for induction of 
long-term potentiation in the medial perforant path. Upregulation of AChRs, assumed to be 
in glutamatergic neurons, was also observed in the anterior cingulate cortex, another region 
involved in cognition (Nashmi et al., 2007). Together, these may explain why cognitive 
enhancement has been observed with nicotine exposure. At more modest and intermittent 
nicotine doses, the transient upregulation in dopaminergic neurons may play a role in 
locomotor sensitization (Baker et al., 2013).
It is important to note that at pharmacologically relevant concentrations of nicotine, found in 
smokers, many AChRs are desensitized (Miwa et al., 2011). Desensitization, like 
“upregulation”, has vastly different uses across biological experiments, occurs on several 
time scales, and has experience a series of meanings since the first report (Katz and Thesleff, 
1957). Neuroscientists now measure desensitization as a decrease in response to agonist 
(i.e., nicotine) after repetitive AChR activation; the extent of desensitization is both time and 
concentration dependent (Karlin, 2002; Katz and Thesleff, 1957; Wang and Sun, 2005). The 
biophysics of desensitization is discussed more fully in 5.5 below. It is not likely that 
activation or desensitization of PM AChRs play a major role in AChR upregulation 
(discussed in sections 4.1 and 4.2); but it is likely that both play a role altering nicotine-
mediated behavior (Picciotto et al., 2008). A key concept is shown graphically in Miwa et 
al., 2011, Figure 3: upregulation of AChRs magnifies the effect of an acute nicotine dose, 
whether the dominant acute effect is activation or desensitization. Desensitization of AChRs 
may contribute to the salience of environmental cues related with smoking behavior 
(Mansvelder et al., 2002; Wooltorton et al., 2003). Both activation and desensitization of 
AChRs may play a role in primary and conditioned drug reward sensation (Brunzell et al., 
2006; Tapper et al., 2004). For an extensive review of this topic, please refer to Picciotto et 
al., (2008).
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3.3 – Upregulation and the addiction to nicotine
Upregulation of AChRs in response to chronic nicotine plays a major role in nicotine 
dependence and, perhaps, in the inverse correlation between a person’s history of tobacco 
use and his or her susceptibility to Parkinson’s disease (PD) (Koob et al., 2004; Koob and 
Volkow, 2009; Ritz et al., 2007; Srinivasan et al., 2014). The fact that AChRs play a critical 
role in the addiction to nicotine is clear, as individual deletions of the α4, α6, or β2 AChR 
subunits are sufficient to block the self-administration of nicotine in mice (Pons et al., 2008). 
Moreover, The selective re-expression of these deleted subunits in the VTA is sufficient to 
re-instate self-administration of nicotine (Brunzell et al., 2010; Pons et al., 2008). Nicotine 
self-administration can be blocked by the selective antagonism of α6* (Jackson et al., 2009) 
or α4* (Yoshimura et al., 2007) AChRs. From this, it is clear that the AChRs mediating 
nicotine addiction include those that contain α4, α6, and β2 subunits (Picciotto et al., 1998; 
Pons et al., 2008; Tapper et al., 2004). The AChR subunits that have been found to 
upregulate with chronic nicotine in vivo include these three (Henderson et al., 2014; Nashmi 
et al., 2007; Staley et al., 2006). Therefore, it is likely that the upregulation of AChRs plays 
a prominent role the reward pathways driving the addiction to nicotine.
3.4 – Reduced ER stress and unfolded protein response
The symptoms of PD arise, in large part, from the selective degeneration of dopaminergic 
neurons. Dopaminergic neurons are subjected to Ca2+ influx and potentially toxic 
byproducts of dopamine metabolites that affect proteostasis (Surmeier et al., 2011). Under 
conditions of physiological stress, dopaminergic neurons display sustained unfolded protein 
responses (UPR). Maintained UPR activates the pro-apoptotic effecter, C/EBP homologous 
protein (CHOP) and this has been suggested to (at least partially) underlie dopaminergic 
neuron cell death in the progression of PD (Mercado et al., 2013). In dozens of retrospective 
epidemiological studies, there is an inverse correlation between a person’s history of tobacco 
use and the risk of developing PD (Hernan et al., 2002; Ritz et al., 2007; Tanner et al., 
2002). We showed how this inverse correlation may be caused by the inside-out 
pharmacology of nicotinic ligands and their ability to reduce ER stress and the UPR 
(Srinivasan et al., 2012). Nicotinic ligands (nicotine, cytisine, and DHβE) reduced nuclear 
translocation of ATF6, a part of the UPR pathway and marker of ER stress. This occurred at 
concentrations that activated 0-0.4% of surface AChRs, showing that AChR activation does 
not play a major role in the reduced ER stress. In addition to its effect on ATF6 
translocation, nicotine also suppressed phosphorylation of eukaryotic initiation factor 2α 
(eIF2α), another component of the UPR pathway. We suggest that as nicotine and nicotinic 
ligands accelerate ER export of AChRs, this suppresses ER stress and the UPR. Suppression 
of sustained UPR may provide an explanation to the apparent neuroprotective effect 
exhibited by nicotine.
We emphasize that reduction of the UPR occurs downstream from pharmacological 
chaperoning but not downstream from upregulation on the PM. Reduction of the UPR is a 
distinct consequence of pharmacological chaperoning by nicotine, but reduction of the UPR 
forms part of “inside-out” nicotinic pharmacology.
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4. Potential Mechanisms of upregulation
4.1 – Outside-in pharmacology?
In cellular neuroscience, it was originally assumed that nicotine-induced upregulation 
resulted from chronic AChR activation, which triggers chronic Na+ and Ca2+ influx, leading 
in turn to a host of intracellular events that eventually “traffic” more AChRs to the PM. This 
assumed mechanism has lost favor since ~ 2005, for the majority of AChR subtypes (Kishi 
and Steinbach, 2006; Kuryatov et al., 2005; Lester et al., 2009; Sallette et al., 2005). The one 
exception may be α7 AChRs, which may upregulate following PM Ca2+ fluxes (Brown et 
al., 2013a) (discussed in section 2.4).
One argument against the AChR activation dependent mechanism is that ion flow through 
AChRs is not necessary for upregulation. In vivo, this has been demonstrated using 
chlorisondamine which causes persistent inhibition of AChR function in mice (el-Bizri and 
Clarke, 1994). Despite this persistent inhibition, AChR upregulation is not prevented 
following chronic treatment with nicotine. In vitro, the non-competitive antagonist (NCA) 
mecamylamine triggers upregulation despite the fact that it has no AChR agonist properties, 
functions as a NCA, and prevents ion flow through AChRs (Kishi and Steinbach, 2006; 
Peng et al., 1994). Mecamylamine had an additive effect with nicotine in its ability to trigger 
upregulation. Additionally, competitive antagonists d-tubocurarine and DHβE have been 
used as evidence that upregulation observed in AChRs does not require AChR activation 
(Kishi and Steinbach, 2006; Peng et al., 1997). Like mecamylamine, DhβE has no agonist 
properties on AChRs, acts as an antagonist; but upregulates AChRs (Kishi and Steinbach, 
2006). Additionally, Kuryatov et al., (Kuryatov et al., 2005) showed that upregulation does 
not require activation of AChRs on the PM using mutations designed to allow nicotinic 
ligands to bind; but fail to gate ions. Here, a mutation found in autosomal nocturnal frontal 
lobe epilepsy patients in the α4 AChR subunit (S247F) was introduced to produce α4β2 
AChRs that do not gate ions upon agonist binding. These mutant AChRs, despite being 
unable to gate ions, still upregulated following chronic nicotine treatment. Together, these 
data suggest that nicotinic ligands are not required to activate AChRs to trigger 
upregulation. However, it is likely that binding to the AChR is necessary (discussed more in 
section 4.5).
4.2 – Desensitization mediated upregulation
Despite a lack of support for the suggestion that AChR upregulation depends on AChR 
activation via an “outside-in” mechanism, a more subtle “outside-in” mechanism has arisen: 
that upregulation may be triggered by the as-yet unknown conformational changes that 
accompany AChR desensitization. Indeed, most AChRs desensitize following prolonged 
exposure (minutes and longer) to nicotine concentrations that only slightly activate PM 
AChRs when applied acutely (< 1 s). Thus, the desensitization hypothesis does allow for the 
common finding that nicotine-induced upregulation occurs at such concentrations 
(Henderson et al., 2014; Richards et al., 2012; Richards et al., 2011; Srinivasan et al., 2011; 
Srinivasan et al., 2012). For instance, in the case of α4β2 AChRs, we observed robust 
upregulation using 100 nM nicotine. This concentration of nicotine is sufficient to activate 
only <4% of surface HS α4β2 AChRs and 0% of LS α4β2 AChRs. In the case of α6β2β3 
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AChRs, we observed robust upregulation using 50 nM nicotine. This concentration of 
nicotine is sufficient to activate <5% of surface α6β2β3 AChRs (Henderson et al., 2014).
There is no evidence that desensitized AChRs on the PM have unique interactions with 
scaffolding proteins, adaptor proteins, kinases, transcription factors, chaperone proteins, 
phospholipids, or other molecules that might regulate their PM levels. “Inside-out” 
mechanisms described below do take account of “desensitized” AChRs, but as an example 
of stabilization by pharmacological chaperoning (see below, section 5.5).
4.3 – Upregulation as a result of conformational change
Vallejo et al., (2005) observed an alternative mechanism of upregulation, extending beyond 
the idea that upregulation is solely an increase in α4β2 AChR number. Two independent 
assays, biotinylation and antibody binding to surface AChRs, were used to document 
significant increase in 125I-epibatidine binding without a significant increase in the number 
of surface AChRs (Vallejo et al., 2005). Here, Vallejo et al., also observed no significant 
change in α4β2 AChR turnover following chronic treatment with nicotine. Interestingly, 
when blocking anterograde trafficking with brefeldin A, Vallejo et al., also found that there 
was no significant change in nicotine-induced increase in epibatidine binding. This suggests 
that trafficking through the secretory pathway is not necessary for creation of upregulated 
AChRs and that upregulation of AChRs may occur through a conformational change. 
Darsow et al., (2005) completed similar studies using brefeldin A, but found opposing 
results to Vallejo et al., (2005). Here, Darsow et al., did note an absence of nicotine-induced 
upregulation when forward trafficking from the ER is blocked with brefeldin A. Here, there 
was also a significant increase in PM α4β2 AChRs following chronic nicotine treatment. In 
considering these opposing results, we note that Vallejo et al., and Darsow et al., used 
different methods and systems: rat AChRs and ≥17.5 h brefeldin A treatment versus mouse 
AChRs and 10 h brefeldin A treatment, respectively (Darsow et al., 2005; Vallejo et al., 
2005).
Govind et al., (2012) propose that upregulation of AChRs involves two components. The 
first component involves the original observations of Vallejo et al., (2005) but is expanded 
by Govind et al., (2012) and includes an event that is independent of an increase in AChR 
number. This component is likely transient, and proceeds faster than AChR degradation. An 
increase in surface AChR binding was detected, despite no increase in AChR number, 
therefore a change in confirmation is likely to be a transition from a resting low-affinity state 
and an ‘upregulated’ high-affinity state that was not associated with changes in AChR 
number (Govind et al., 2012; Vallejo et al., 2005). This event, in the context of this review, 
would be an “outside-in” mechanism.
During prolonged exposure to nicotine, AChR channels on the PM begin to close; and the 
earliest thermodynamic analysis suggested that these “desensitized” AChRs have higher 
affinity and altered conformation (Katz & Thesleff, 1957). In one interpretation, Vallejo et 
al., (2005) and Govind et al., (2012) may have found that additional exposure to agonists 
(e.g., nicotine) leads to further conformational changes, and to further increases in affinity, 
of these closed PM AChRs.
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The second component proposed by Govind et al., (2012) actually occurs at an earlier step 
in AChR biosynthesis. The second component is caused by an increase in AChR number, 
distinct from the conformation-based mechanism. This second component involves the 
longer-lasting process of increased AChR number, resulting from reduced ER degradation, 
increased subunit assembly, and consequently, increased insertion of AChRs on the PM 
(Govind et al., 2012). Component two, in the context of this review, would be an inside-out 
mechanism, in agreement with many findings that have led to the proposal of inside-out 
nicotinic ligand chaperoning (Kishi and Steinbach, 2006; Kuryatov et al., 2005; Lester et al., 
2009; Sallette et al., 2005; Srinivasan et al., 2011)(discussed further in following sections). 
In the context of blocking exocytic machinery with brefeldin A, Vallejo et al., presents an 
argument that in addition to changes in AChR stoichiometry (Lester et al., 2009; Srinivasan 
et al., 2011), changes in AChR number (Darsow et al., 2005; Henderson et al., 2014; 
Richards et al., 2011; Srinivasan et al., 2011), and changes in AChR sensitivity (Kuryatov et 
al., 2005), an additional change may occur, without trafficking, among AChRs.
Therefore in addition to the inside-out mechanisms that are described throughout this 
review, the Green lab finds evidence for an additional, perhaps complementary event: 
AChRs on the PM undergo a conformational change that results in higher-affinity AChRs.
4.4 – Does upregulation depend on basal PM density of AChRs?
An interesting finding in the study by Sallette et al., (Sallette et al., 2004) was that α3β4 
AChRs maintained a high basal PM density (~3-fold higher than β2* AChRs) in addition to 
their observed resistance to upregulation. This occurs with α4β4 AChRs as well as α3β4 
AChRs (Henderson et al., 2014; Richards et al., 2011; Srinivasan et al., 2011).
One key difference among β2* and β4* AChRs that likely clarifies this divergence are the 
differences in export and retention motifs found in each subunit (Srinivasan et al., 2011). 
The β4 AChR subunit contains an ER export motif that is not found in the β2 AChR subunit. 
Additionally the β4 AChR subunit lacks an ER retention motif that is found in the β2 AChR 
subunit. Together, these key differences lead to a more efficient export from the ER of β4* 
AChRs when compared to β2* AChRs. These data imply that upregulation may be 
influenced by the basal density of a particular AChR subtype on the PM. For example, β4* 
AChRs, due to their efficient ER export, may not upregulate since they maintain a high basal 
PM density (Henderson et al., 2014; Richards et al., 2011; Sallette et al., 2004; Srinivasan et 
al., 2011). As stated explicitly by Sallette et al., (Sallette et al., 2004) “α3β4 AChRs are 
constitutively upregulated, whereas α3β2 AChRs are weekly expressed, a feature 
surmounted by nicotine action.”
Additional evidence for this can be seen in the study presented by Srinivasan et al., 
(Srinivasan et al., 2011). Here, β2 AChR subunits were mutated to introduce the ER export 
motif found in the β4 AChR subunit (L349M) and the ER retention motif (found in the β2; 
but not in the β4 AChR subunit) was disrupted (365AAQA368). These mutated α4β2 
(α4β2DM) AChRs exhibited a >2-fold increase in basal PM density compared to WT AChRs 
as a result in a greatly increase in the efficiency of anterograde trafficking. Interestingly, 
when these AChRs were exposed to nicotine only a small increase in PM density was 
observed (<20%).
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In all cases where high basal PM density is observed (α4β4, α3β4, and α4β2DM AChRs), 
there has also been an observation of maximal anterograde trafficking of these AChRs 
(Richards et al., 2011; Srinivasan et al., 2011). Although the high basal PM density is the 
most readily observable feature, it may be more appropriate to suggest that the resistance of 
β4* AChRs is a result of their highly efficient export from the ER. Rather, β4* AChRs may 
be unaffected by pharmacological chaperoning because their already efficient export fulfills 
the roles played by maturation and pharmacological matchmaking.
4.5 – Upregulation as a result of increased AChR stability (decreased turnover)
It has been suggested that the increase of AChR number on the PM is a result of nicotine or 
nicotinic ligands stabilizing surface AChRs so that they are degraded or internalized more 
slowly. Evidence of this has been presented by Peng et al., (Peng et al., 1994). Here it was 
shown that AChRs treated with nicotine remain on the PM ≥4 days following inhibition of 
protein synthesis while in untreated conditions, AChRs on the surface are degraded to <50% 
of their original population in 24 hours. It is important to mention that this was observed 
using 5 μM nicotine. This is a concentration much higher than pharmacologically relevant: 
10-100 times higher than observed in nicotine exposure through smoking (50-500 nM).
Kuryatov et al., (Kuryatov et al., 2005) used a more pharmacologically relevant 
concentration of nicotine (500 nM) in a surface biotinylation study. Here, it was 
demonstrated that α4β2 AChRs turnover with a half-life of 12.6 hours. Following nicotine 
treatment, the half-life was increased to 62.8 hours. This is strong evidence for the case of 
nicotine’s ability to increase AChR stability on the PM. Not all reports of AChR turnover 
are in agreement. It is quite possible that nicotine does not alter AChR stability on the PM. 
Vallejo et al., Darsow et al., and Sallette et al., (all 2005) showed that AChR turnover is not 
altered by chronic nicotine treatment using concentrations of 10 μM, 100 μM, and 1 mM, 
respectively. These three studies, while above pharmacologically relevant concentrations of 
nicotine, still provide evidence that AChR stability and turnover may not be altered by 
chronic nicotine exposure.
We have shown that chaperoning involves a process of increased anterograde traffic of 
stable AChR pentamers to the PM (Henderson et al., 2014; Richards et al., 2011). Using 
pharmacologically relevant concentrations of nicotine (50 or 100 nM) we have shown that 
chronic nicotine increases the rate of α4* and α6* AChR insertion onto the PM (Henderson 
et al., 2014; Richards et al., 2011; Srinivasan et al., 2011). As noted above, we believe that 
this increased insertion rate is a consequence of an increased pool of AChRs awaiting 
contact with the final steps of exocytosis machinery, not of a molecular modification in the 
exocytotic machinery. At this point, it is still not clear if increased stability (reduced 
turnover) is a contributor to AChR upregulation. If so, it is likely a component that is 
synergistic with increased insertion of AChRs onto the PM.
4.6 Binding of nicotinic ligands is a critical step in initiating upregulation
Even if activation and desensitization of AChRs do not contribute to upregulation, the 
binding of nicotinic ligands is necessary for the process of upregulation (Kishi and 
Steinbach, 2006). Mutating residues that are known to contribute to binding of nicotine and 
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nicotinic ligands in the agonist binding site (W182F, W82F, and Y223F) resulted in a 
reduction or absence upregulation by nicotinic ligands (Kishi and Steinbach, 2006). At 
pharmacologically relevant concentrations of nicotine, mutations α4W182F, α4Y223F, 
α4Y126F, or β2W82F resulted in little or no upregulation (≤0.5 fold) of α4β2 AChRs when 
compared to WT α4β2 AChRs (~2.5 fold upregulation) (Kishi and Steinbach, 2006). Similar 
trends were observed for other nicotinic ligands: lobeline, carbamylcholine, and DhβE. 
Upregulation of these mutated AChRs occurred to some degree; but it was clear that the 
EC50 of upregulation and efficacy of upregulation were altered significantly upon mutating 
residues that contribute to the agonist binding site. This effect on AChR upregulation 
strongly suggests that binding to AChRs is necessary for upregulation.
It is a frequent result that nicotine concentrations required for upregulation, although far less 
than required to activate PM AChRs, are far greater than the steady-state Kd in equilibrium 
binding experiments at these AChRs (Gopalakrishnan et al., 1996; Kishi and Steinbach, 
2006; Kuryatov et al., 2008). This also occurs with other nicotinic ligands: the concentration 
dependence for lobeline and DHβE does not match the steady-state affinities on resting or 
desensitized AChRs (Kishi and Steinbach, 2006). This suggests that the binding site of 
nicotinic ligands in triggering upregulation may not be to stable, mature pentamers. Kishi et 
al., (Kishi and Steinbach, 2006) suggest that these nicotinic ligands, are in fact binding to 
immature AChRs that reside in intracellular organelles.
4.7 – Inside-out pharmacology
The evidence gathered suggests an intracellular (“inside-out”) mechanism for nicotinic 
ligands in their ability to upregulate AChR number on the PM. Activation and 
desensitization based mechanisms have been proven unsatisfactory as AChR activation is 
not necessary. In parallel with evidence that activation of AChRs on the PM is not critical 
for upregulation to occur, other evidence suggests that nicotinic ligands manipulate 
upregulation through intracellular mechanisms. It is likely that AChR assembly in the ER 
and export through the secretory pathway is a rather inefficient process and the rate limiting 
step may occur at the level of the ER (Henderson et al., 2014; Srinivasan et al., 2011). Over 
the years we, along with several others, have begun to dissect the key intracellular events 
that manipulate upregulation. These include: 1) pharmacological chaperoning, 2) 
pharmacological matchmaking, and 3) Golgi-ER cycling. These will be covered explicitly in 
the following sections.
5. Inside-out pharmacology of nicotinic ligands
5.1 – Nicotinic ligands readily permeate membranes to act as pharmacological chaperones
A pharmacological chaperone is a small molecule that stabilizes a protein by binding, as a 
substrate, agonist, antagonist, or allosteric modulator, at a pharmacologically relevant site on 
the target protein. This stabilization process is often associated with the pharmacological 
chaperone facilitating a protein in reaching its stable, low energy conformation (See Figure 
2A). Binding primarily occurs within an organelle and typically occurs during biosynthesis 
and early trafficking of the target protein (Lester et al., 2012). Upon binding, a 
pharmacological chaperone facilitates the protein’s movement through the secretory 
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pathway. Eventual insertion into the PM appears as usual. A pharmacological chaperone 
should not be confused with a chaperone protein; but the effect may be similar.
A critical component to the inside-out actions of nicotinic ligands is that nicotine readily 
passes through membranes to reach intracellular organelles. The process begins anew ~150 
billion times a day, when a smoker puffs or vapes. Within 20 s, nicotine then permeates six 
membranes: in the lungs, endothelium of brain capillary and astrocytic end-feet (see Figure 
3). Although there are hints of saturable, carrier-mediated transport in one or more of these 
membranes (Cisternino et al., 2013), most researchers agree that the simple membrane 
permeability of deprotonated nicotine accounts for most of this flux. This strongly suggests 
that nicotine may also enter intracellular organelles like the ER and Golgi (Kuryatov et al., 
2005; Sallette et al., 2005; Xiu et al., 2009). It has been shown that many tertiary ligands, in 
addition to nicotine, permeate cell membranes and enter intracellular organelles (ER and 
Golgi) to upregulate AChRs (Kuryatov et al., 2005). These ligands cross the PM and 
intracellular membranes in their uncharged forms within minutes. This was exhibited when 
ligands such as nicotine and epibatidine, within a 20 minute incubation, proceeded to block 
all specific binding of [3H]nicotine on α4β2 AChRs (Kuryatov et al., 2005).
It is often asked whether a single “compartmentalization” experiment can provide a decisive 
distinction between outside-in and inside-out pharmacology. The answer is negative, as even 
molecules that are relatively impermeant on a time scale of seconds eventually enter cells. 
We believe that so-called “impermeant” drugs lose this adjective on times scales greater 
than ~2 h, so that upregulation and other aspects of pharmacological chaperoning, which 
occur over hours, days, and weeks, cannot be decisively tested with such drugs. For 
instance, quaternary amines (e.g., DMPP, ACh) may penetrate cells and trigger 
upregulation; but they require longer periods of time (~3 h) to do so when compared to 
nicotine and tertiary amines (Kuryatov et al., 2005).
It seems intuitive that nicotinic agonists such as cytisine, DMPP, and carbamylcholine are 
able to upregulate AChRs since they bind similarly to nicotine at the orthosteric site of 
AChRs (Kuryatov et al., 2005; Peng et al., 1994). Interestingly, even NCAs and allosteric 
modulators that do not bind to the orthosteric site, such as mecamylamine, have been shown 
to upregulate AChRs as well (Peng et al., 1994). The caveat is that this may require high 
concentrations (nearly mM) to do so. Some competitive antagonists have been shown to 
upregulate AChRs (i.e., DhβE) (Kuryatov et al., 2005). (−)-Lobeline, an AChR partial 
agonist (Farook et al., 2009), which also acts as an antagonist (Damaj et al., 1997), also 
upregulates AChRs (Kishi and Steinbach, 2006). Large, competitive antagonists, such as d-
tubocurarine, are unable to upregulate AChRs and even prevent upregulation (Peng et al., 
1994).This may be due to the fact that d-tubocurarine (and many competitive antagonists) is 
quaternary, large, and complex. As a result, d-tubocurarine may poorly penetrate cell 
membranes.
5.2 – Maturational enhancement
During the maturation process of AChRs, a sequence of glycosylation states typically appear 
(Sallette et al., 2005). Mature pentameric AChRs require complex glycosylations and 
trimming for successful export to the PM. Using metabolic labeling assays, Sallette et al., 
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(Sallette et al., 2005) established that maturation of AChRs is a slow, inefficient process; but 
the speed and efficiency increase dramatically with nicotine treatment. Under basal 
conditions, 60% of α4 and β2 AChR subunits resident in the ER are glycosylated in the 
course of subunit processing while the remainder are degraded by cellular machinery. With 
nicotine treatment, > 90% of these AChR subunits become glycosylated. This process 
occurs shortly (as early as 30 minutes) after protein synthesis. Although maturation is a 
multi-step process, the model suggested by Sallette et al., (Sallette et al., 2005) clearly 
shows that nicotine promotes an early step in maturation of subunits that would otherwise be 
degraded, thereby increasing the number and stability of AChR subunits available for 
formation of stable, mature pentamers.
5.3 Pharmacological Matchmaking
It appears that nicotine binds to nicotine-sensitive precursors to promote a critical subunit-
subunit interaction step that is limited in the processing of AChR subunits (Kuryatov et al., 
2005; Sallette et al., 2004; Sallette et al., 2005) (depicted in Figure 2C). Our colleague 
Dennis Dougherty suggests that we summarize this increase in subunit-subunit interaction 
“pharmacological matchmaking” to distinguish it from “pharmacological chaperoning”.
There is an abundance of examples documenting this nicotine-induced increase in subunit-
subunit interactions. Chronic nicotine treatment induces a dramatic increase in the co-
immunoprecipitation between α4 and β2 AChR subunits in the ER, suggesting that nicotine 
increases subunit-subunit interaction (or assembly) of AChRs in the ER (Kuryatov et al., 
2005; Sallette et al., 2005; Wang et al., 1998). Similarly, chronic nicotine treatment 
increases FRET among α4 and β2 AChR subunits, further suggesting that nicotine increase 
subunit-subunit interactions (Henderson et al., 2014; Son et al., 2009; Srinivasan et al., 
2011). These FRET assays used whole-cell sections. Thereby, the observed FRET included 
AChRs resident both on the PM and within organelles. Given that transfected cells, as used 
in these assays, exhibit a large pool of AChRs in the ER (Kuryatov et al., 2005; Sallette et 
al., 2004; Sallette et al., 2005), it is likely that the majority of the observed FRET originates 
in intracellular organelles such as the ER (Moss et al., 2009). Using fluorescently tagged 
GalT, a marker for the trans-Golgi and trans-Golgi network (TG/TGN), selective 
examination of AChR assembly and stoichiometry in the TG/TGN is possible. Without 
nicotine treatment, a relatively equal proportion of high- and low-sensitivity stoichiometries 
of α4β2 AChRs are assembled in the TG/TGN (Srinivasan et al., 2011). Following nicotine 
treatment, a higher proportion of high-sensitivity α4β2 AChRs reside in the TG/TGN. This 
suggests that following chronic nicotine treatment, more HS α4β2 AChRs are assembled in 
the ER and subsequently chaperoned to the TG/TGN. Together, these FRET and 
immunoprecipitation assays support the hypothesis that nicotine acts as a matchmaker, 
increasing the subunit-subunit interactions of AChRs in ER, and chaperones AChRs through 
the secretory pathway to the TG/TGN, and finally to the PM.
5.4 Pharmacological Matchmaking and Maturational enhancement: importance of an 
extracellular microdomain
Systematic analysis of β2/β4 chimeras by Sallette et al., (Sallette et al., 2004) demonstrated 
that the extracellular domain may contribute a critical process for upregulation. Here it was 
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shown that, residues 74-89 and 106-115 of the β2 AChR subunit’s extracellular domain 
greatly influence upregulation (Sallette et al., 2004). The β2 AChR residues of interest are 
near the subunit interface, face the orthosteric (agonist) binding site, and may play a key role 
in the pharmacological matchmaking process as a recognition site for nicotinic ligands. In 
this study, it was shown clearly that α3β2 AChRs are more responsive to upregulation when 
compared to α3β4 AChRs (as mentioned above), albeit at non-pharmacologically relevant 
concentrations of nicotine (≥1 mM). Sallette et al., (Sallette et al., 2004) created chimeric β4 
AChR subunits containing the residues 74-89 and 106-115 of β2 AChR subunits; these 
α3β4Mutant AChRs upregulated to the same degree as α3β2 AChRs. Furthermore, Sallette 
et al., (Sallette et al., 2004) proposed that nicotine binds to immature AChR subunits, 
initiates conformational reorganization of this microdomain and this results in an enhanced 
interaction among AChR subunits which expedites the maturation process. This suggests 
that pharmacological matchmaking plays a role in the enhancement of the maturation 
process. We mentioned earlier that β2* and β4* AChRs may be differentially chaperoned by 
nicotinic ligands due to differences in retention and export motifs. The study by Sallette et 
al., (Sallette et al., 2004) focused exclusively on the extracellular domain in regions close to 
the subunit interfaces. This suggests that in additional to our knowledge about AChR 
retention and export motifs, a critical component that occurs at the interfaces of AChR 
subunits that allows matchmaking and maturational enhancement by nicotinic ligands to 
occur.
More recently, computational modeling has provided additional insights into interactions 
between nicotine and AChR subunits that may explain how the matchmaking and 
maturational enhancement process occurs. Gao et al., (Gao et al., 2005) showed that as ACh 
binds to the orthosteric site, conserved tryptophan residues from the principal and 
complementary subunits begin to form non-covalent interactions, most likely hydrogen 
bonds. These interactions may act as a ‘molecular glue’ and may be shared by other 
nicotinic drugs to stabilize the association of α and β AChR subunit intermediates through 
pharmacological matchmaking. Molecular dynamics have also provided insight into how 
ACh, nicotine, and other nicotinic ligands affect closure of the C-loop (Gao et al., 2005; 
Henderson et al., 2010; Pavlovicz et al., 2011b). Upon binding, agonists, partial agonists, 
antagonists, and allosteric modulators allow the C-loop to close with variable distances 
which allow additional non-covalent interactions with the complementary interface of an 
adjacent AChR subunit. This event is likely to provide another level of stabilization for 
pharmacological matchmaking and may play a significant role in the enhancement of the 
maturation process.
5.5 – Desensitization and conformational change in the context of pharmacological 
chaperoning
Inside-out mechanisms arise in part because agonists allow AChRs to reach additional 
states, beyond the resting states stabilized by antagonists (Figure 2A), both on the PM and 
inside the cell. Classical electrophysiological observations at the PM show that these 
additional states (the most detectable is the “channel-open state”) are metastable. We use the 
term in the same sense that after a depolarizing voltage jump, an open voltage-gated Na+ 
channel is metastable (Hille, 2001). Indeed the trace in Figure 2A resembles a conductance 
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vs time trace for Na+ channels, a thousand times more slowly. When AChRs reside in open 
states for longer periods they can eventually, stochastically, surmount the energy barriers 
separating the open states from neighboring, additional states. Some of these neighboring 
states are more stable than open states (Jensen et al., 2005). Most of these more stable states 
have closed channels. There may be a selective advantage in these closings, for they avoid 
excitotoxic damage to neurons. There are doubtless several such closed states, accessible at 
increasingly prolonged times of agonist application as the agonist-receptor complex reaches 
states of lower free energy. When the AChR is on the PM, these increasingly stable closed 
states are loosely termed “desensitized”. Again there is a strong analogy with the several 
“inactivated” states of voltage-gated Na+ channels. We actually have no information about 
the number of “desensitized” states or their structure. However decades of research on 
desensitization states, and simple thermodynamics, assures us that that desensitized states 
bind agonist more tightly than either the resting or open-channel states (Albuquerque et al., 
2009). This latter aspect of desensitization has no good parallel in Na+ channels. As 
expected from this explanation, the spectrum of stabilities of the stabilized states have led to 
suggestions that these states also have a spectrum of affinities for nicotine (Feltz and 
Trautmann, 1982).
Because of the strong evidence that ligands can also bind to AChRs inside cells (Whiteaker 
et al., 1998), agonists in particular can ease the transition to more stable states for AChRs 
inside cells. This is pharmacological chaperoning. We have very little information about 
these more stable states or their number; but some more stable states may have modified 
antigenicity (see section 4.3 above). Whether any of these more stable states are open is 
presently unknown and, in fact, unimportant for pharmacological chaperoning as presently 
conceived, because pharmacological chaperoning does not occur via ion fluxes (Kuryatov et 
al., 2005). The important aspect is that such stabilization helps to retard AChR degradation 
in the early secretory pathway (Mazzo et al., 2013; Sallette et al., 2005). Thus, in the present 
context the ready observability of desensitization at the PM exemplifies how agonists allow 
AChRs to find stable states within cells and on the PM.
5.6 – Intracellular cycling is necessary for upregulation
We, along with others, have demonstrated that chronic nicotine treatment enriches the ER 
with assembled AChRs (Henderson et al., 2014; Mazzo et al., 2013; Sallette et al., 2005; 
Srinivasan et al., 2011; Whiteaker et al., 1998). As mentioned above, this is the result of 
pharmacological matchmaking and maturational enhancement as a product of the inside-out 
pharmacology of nicotinic ligands.
One of the earlier observations concerning nicotine altering intracellular trafficking or 
exocytic machinery came from Darsow et al., (2005). Here, it was shown that brefeldin A, 
an inhibitor of transport from the ER to Golgi, prevents nicotine-induced upregulation. This 
indicates that nicotine exploits early exocytic machinery to upregulate AChRs. We have 
found that the increase in partially mature AChR pentamers leads to an increase in coat 
protein complex II (COPII) mediated anterograde traffic through the secretory pathway 
(Srinivasan et al., 2011). Sec24D, a component of the COPII machinery, can be used to 
identify ER exit sites, locations where ER resident proteins are packaged into COPII 
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vesicles for export through the secretory pathway. Chronic nicotine dramatically increases 
the number of ER exit sites and the density of AChRs in ERES, indicating that export from 
the ER toward the PM is increased with nicotine (Henderson et al., 2014; Srinivasan et al., 
2011; Srinivasan et al., 2012). Additionally, we have reported that chronic nicotine also 
increases the rate of insertion of AChRs on the PM (Henderson et al., 2014; Richards et al., 
2011). As the density of AChRs increases in the ER, more stable pentameric AChRs are 
loaded into COPII export vesicles to move through the secretory pathway from the ER, to 
the ER Golgi intermediate compartment, to the Golgi, and then to the PM.
In addition to COPII mediated ER export, retrograde movement mediated by coat protein 
complex I (COPI) is an essential component to the upregulation of AChRs via nicotinic 
ligands (Henderson et al., 2014). COPI mediates retrograde traffic from the Golgi back to 
the ER and recognizes its cargo by binding to di-lysine motifs (KKxx or KxKxx) (Jackson et 
al., 2012; Ma and Goldberg, 2013). We used α6β2β3 AChRs as a model to investigate the 
importance of COPI in AChR upregulation, as the β3 mouse AChR subunit contains a KKK 
motif which satisfies both di-lysine motifs recognized by COPI (Henderson et al., 2014). 
Using mutations of the putative COPI retrieval motif in the β3 AChR subunit and an 
antagonist of COPI (CI-976) we showed that AChRs fail to upregulate when the interaction 
with COPI is prevented (Henderson et al., 2014). Upon inhibition of COPI retrograde traffic, 
there was a consequent increase of AChR density in the Golgi and a decrease of AChR 
density in the ER (Henderson et al., 2014). Despite this, there was no significant change in 
ERES. This indicates that there was no significant change in COPII mediated ER export. 
Interestingly, the basal levels of AChRs on the PM did not change when we compared the 
chronic nicotine treatment group to the no drug treatment group, following inhibition of 
COPI. When COPI function is normal, chronic nicotine treatment increases interactions 
between COPI and AChRs (as reported by FRET) and increases the density of AChRs in 
COPI vesicles (Henderson et al., 2014).
Perhaps many of the AChRs that reach the Golgi under upregulated conditions are still not 
fully ‘mature’. Instead of being targeted for traffic to the PM, they may fail a quality control 
check at the level of the Golgi and are then retrieved back to the ER, via COPI, for 
additional processing (additional post-translational modifications). Maturational 
enhancement by nicotinic ligands may assemble AChRs in a way that is premature. That is, 
their processing may occur at a rate that exceeds the capacity of post-translational 
modifications. Thereby, AChR pentamers that undergo maturational enhancement by 
nicotinic ligands are chaperoned out of the ER before they complete the required post-
translational modifications that are required to exit the Golgi and be inserted into the PM. 
Therefore the cycling between the Golgi and ER may be a necessary and critical component 
to circumvent this deficiency and insure that only fully ‘mature’ AChRs reach the PM. 
When we add the fact that COPI interactions with AChRs and the AChR density in COPI 
vesicles increases following chronic nicotine treatment (Henderson et al., 2014), this 
argument is strengthened.
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5.7 – Nicotinic ligands differentially chaperone AChRs
AChRs come in many different assemblies and some exhibit different stoichiometries. As 
mentioned, α4β2 AChRs are known to exist in either a high-sensitivity stoichiometry 
((α4)2(β2)3) or a low-sensitivity stoichiometry ((α4)3(β2)2) (Nelson et al., 2003; Tapia et al., 
2007). The term ‘high’ and ‘low’ sensitivity comes from the affinity and potency that 
nicotine exhibits on these two AChR stoichiometries. Nicotine selectively upregulates HS 
α4β2 AChRs (Kuryatov et al., 2005; Nelson et al., 2003; Son et al., 2009; Srinivasan et al., 
2011; Tapia et al., 2007). When one considers the affinity of nicotine for HS α4β2 AChRs 
versus LS α4β2 AChRs (~100-fold higher (Kuryatov et al., 2005; Nelson et al., 2003)), this 
may explain how nicotine would act as a selective pharmacological chaperone for HS α4β2 
AChRs and not for LS α4β2 AChRs. Further details will need to be revealed to fully 
understand the selective chaperoning of HS α4β2 AChRs. Despite being HS or LS, both 
stoichiometries of α4β2 AChRs contain (α4β2)2 and therefore two ‘high-affinity’ binding 
sites. The difference may be in how nicotine may interact with the interface of the auxiliary 
subunit whether it is α4 or β2. Recently, it was discovered that nicotinic ligands do bind to 
non-canonical binding sites with high affinity (Eaton et al., 2014). This has been 
characterized for the α4-α4 interface of LS α4β2 AChRs; but we do not know what may 
occur at the β2-β2 AChR interface of HS α4β2 AChRs.
Cytisine is a partial agonist that exhibits similar efficacy on both LS and HS α4β2 AChRs 
(Kuryatov et al., 2005). Cytisine exhibits robust upregulation of α4β2 AChRs (Kuryatov et 
al., 2005); but cytisine exerts different effects than nicotine. Chronic treatment with cytisine 
results in a PM population that favors LS α4β2 AChRs (Richards et al., 2012; Srinivasan et 
al., 2012). Essentially, cytisine primarily chaperones LS α4β2 AChRs. Recent data show 
that another nicotinic ligand likely chaperones low sensitivity α4β2 AChRs (Nichols et al., 
2014). The endogenous allosteric modulator, lynx1, is well known for its role in 
‘optimizing’ cholinergic tone via AChRs (Miwa et al., 1999; Miwa et al., 2012; Miwa et al., 
2006). The apparent difference in AChR sensitivity to ACh in the absence and presence of 
lynx1, is likely due, in part, to lynx1 acting as a chaperone for LS α4β2 AChRs (Nichols et 
al., 2014). Lynx1 appears to stabilize α4-α4 AChR subunit dimers in the ER, as seen in co-
immunoprecipitation, electrophysiological, and FRET assays (Nichols et al., 2014). This is 
similar to the way in which nicotine stabilized α4-β2 subunit dimers in co-
immunoprecipitation assays (Sallette et al., 2005). Furthermore, this effect seems to be 
initiated in the ER (Nichols et al., 2014).
The fact that different nicotinic ligands chaperone a single type of AChR (α4β2), but with 
preference for different stoichiometries, suggest that there may be some specificity to the 
matchmaking and pharmacological chaperoning process depending on the nicotinic ligand. 
In the case of nicotine, we see agreement between the type of stoichiometry that is 
chaperoned and the sensitivity that nicotine has for that particular stoichiometry. Cytisine 
seems to activate, stabilize, and chaperone the other stoichiometry.
It is reasonable, on a thermodynamic basis, that nicotinic ligands chaperone the AChR 
subtype or stoichiometry in which they bind best. The case of lynx1 is however not a 
decisive test of this hypothesis. To clarify, lynx1 is the probable evolutionary antecedent to 
the snake venom toxin, α-bungarotoxin and lynx1 stabilizes α4-α4 AChR subunit interfaces 
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(Miwa et al., 2012; Nichols et al., 2014). Recall that α-bungarotoxin (Miwa et al., 2012; 
Nichols et al., 2014) selectively binds to α7-α7 interfaces; but α-bungarotoxin also binds 
tightly to α-nonα interfaces of muscle AChRs. It is not known how lynx1’s affinity for α-α 
and α-β interfaces compares, as the GPI anchor complicates binding studies. Evidently 
lynx1 should be viewed as an incompletely understood blend of a pharmacological 
chaperone and a chaperone protein.
How is it that NCAs chaperone AChRs? We have thus far presented an intracellular 
mechanism where nicotinic ligands bind AChRs, foster maturational enhancement, stabilize 
nascent AChR pentamers, and chaperone AChRs through the secretory pathway to the PM. 
This has been suggested to depend upon binding at the agonist site (Kishi and Steinbach, 
2006; Sallette et al., 2004). The upregulation of AChRs by competitive antagonists (e.g., 
DhβE) can be explained by the fact that they bind to the same site as nicotine and other 
nicotinic agonists (Hansen et al., 2006; Hansen et al., 2005; Pavlovicz et al., 2011a). On the 
other hand, NCAs, such as mecamylamine, do not bind the agonist site and chaperoning 
cannot be explained as clearly it is for nicotinic ligands that bind the orthosteric site. It is 
possible that binding at other sites, still at the interface of α and β AChR subunits may be 
sufficient. Mecamylamine likely binds within the luminal and non-luminal regions of the 
transmembrane domain at the interface of AChR subunits (Bondarenko et al., 2014; Charnet 
et al., 1990; Leonard et al., 1988). The binding of mecamylamine to the interface of these α4 
and β2 AChR subunits may be sufficient, as a “matchmaking” event, to enhance maturation.
6. Summary: inside-out actions of nicotinic ligands
Many ligands have been shown to upregulate AChRs: agonists (ACh, epibatidine, nicotine, 
MCC, DMPP, cytisine), antagonists (mecamylamine, DhβE), and allosteric modulators 
(lynx1, genistein). We know that AChR upregulation is not triggered by activation or 
desensitization (see section 4.1 and 4.2); upregulation is triggered by binding of nicotinic 
ligands to AChRs in intracellular compartments (Kishi and Steinbach, 2006). Furthermore, 
this binding event does not occur on mature AChRs, but on immature AChRs which likely 
reside in the ER (see Figure 2 and Figure 3). Thus, AChR upregulation likely is initiated by 
a series of events that start in the ER and progress throughout the secretory pathway (See 
Figure 3).
First, nicotinic ligands enter organelles such as the ER and Golgi (Henderson et al., 2014; 
Kuryatov et al., 2005; Srinivasan et al., 2011). Here, nicotine or nicotinic ligands stabilize 
nascent AChR pentamers. By increasing assembly of dimers and trimers into pentamers, 
nicotinic ligands act as a ‘matchmaker’ or maturational enhancer (Sallette et al., 2005). 
Second, these additional AChR pentamers remain stabilized by nicotinic ligands that reside 
in the ER and are targeted for ER export via COPII. The increase of AChR pentamers in the 
ER results in an increase of ERES; thereby more AChR pentamers are packed in COPII 
vesicles that leave the ER and pass through the ER-Golgi intermediate compartment to reach 
the Golgi. Third, at the level of the Golgi there exists an incompletely understood 
mechanism, such as a quality control check, that prevents some ‘upregulated’ AChRs from 
exiting the Golgi to reach the PM. Regardless of the specific mechanism, many chaperoned 
AChRs are retrieved back to the ER via COPI (Henderson et al., 2014). Regarding Golgi-ER 
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cycling of AChRs, nicotinic ligands may remain bound to AChRs while the AChRs reside in 
COPI and/or COPII vesicles. Here, processes related to pharmacological chaperoning 
and ’matchmaking’ may occur in these vesicles similarly to their binding in the ER and 
Golgi. Fourth, as nicotinic ligands increase the density of stable AChRs in the secretory 
pathway, the density of AChRs in secretory vesicles increase and the number of vesicles that 
are deployed to the PM increases paripassu (Henderson et al., 2014; Richards et al., 2011). 
Finally, once on the PM, AChRs might also remain stabilized by nicotinic ligands, reducing 
turnover and contributing to the increase in AChR number on the PM (Peng et al., 1994). As 
export from the ER increases with chronic treatment of nicotinic ligands, ER stress and the 
UPR is reduced. Nuclear ATF6 translocation and phosphorylation of eIF2α (markers of ER 
stress and the UPR) are attenuated by nicotinic ligands (Srinivasan et al., 2012). As a result, 
pro-apoptotic signaling is weakened and neuroprotection may occur.
7. Conclusion and Future Directions
As we continue to study the mechanistic basis of AChR upregulation, it becomes 
increasingly clear that many of the critical components occur in intracellular environments. 
It is likely that one locus is the ER; but we now know that the Golgi plays a significant role 
through the traffic of AChRs via COPI and COPII. In understanding the inside-out 
pharmacology of nicotinic ligands, we may be able to develop new therapies for addiction to 
nicotine (Lester et al., 2012; Lester et al., 2009) or for neuroprotection against PD 
(Srinivasan et al., 2014). Currently, most drug discovery efforts involve designing and 
optimizing ligands to be specific for AChR subtypes (likely α6* or α4* AChRs). However, 
it is quite possible that the therapeutic molecules found to be most effective in nicotine 
cessation or neuroprotection against PD will be the ones that are optimized for entry into the 
ER and for their ability to modulate maturational enhancement, matchmaking and 
chaperoning. These hypothetical ligands would be optimized based upon their affinity for 
specific subunit interfaces as opposed to their efficacy on PM AChRs. The state diagram of 
Figure 1A shows that it is unlikely that simple antagonists are likely targets to become 
pharmacological chaperones. However, inverse agonists, allosteric modulators (positive and 
negative), and noncompetitive channel blockers may stabilize AChRs quite effectively and 
likely in a manner similar to nicotine. In fact, allosteric modulators may be preferred as they 
do not interact with the orthosteric site and possess more potential for subtype-selective 
interactions (Henderson et al., 2012; Henderson et al., 2010).
In other biomedical fields, such as cancer and cystic fibrosis, it is taken for granted that a 
molecule with logP > 1 permeates cell membranes and binds to its targets intracellularly. 
Yet most neuroscientists, even today, remain skeptical when informed that nicotine may act 
intracellularly on the same targets that pass through the ER on their journey to the PM. We 
continue to assure our colleagues that the acute effects of nicotine follow “outside-in” 
mechanisms; but we continue to encounter resistance to the idea that some chronic effects 
follow “inside-out” pathways. Although several mechanistic uncertainties remain, this 
review may convince a few more skeptics.
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• Nicotinic ligands enter endoplasmic reticulum (ER) and bind to some nicotinic 
receptors (AChRs).
• This “pharmacological chaperoning” alters traffic within early secretory 
pathways.
• As a result, chronic exposure to nicotinic ligands upregulates some AChRs.
• These results of intra-organellar binding are termed “inside-out pharmacology”.
• “Inside-out” effects also modify ER stress and the unfolded protein response.
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Figure 1. 
Structures of agonists (A), competitive antagonists (CA), non-competitive antagonists 
(NCA), and positive allosteric modulators (PAM) of AChRs. With the exception of d-
tubocurarine, all molecules shown have been reported to upregulate AChRs.
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Figure 2. Three possible results of nicotinic ligand-AChR binding in the ER
(A) Nicotinic ligand binding eventually favors stable, high-affinity states (a “chaperone”). 
(B) Nicotine may displace lynx, directing AChRs toward cholesterol-poor domains (an 
“escort” or “abductor”). (C) Nicotinic ligand binding at subunit interface acts as a 
maturational enhancer (a “matchmaker”) and results in the increased assembly of stable 
pentamers.
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Figure 3. Evidence Supporting Inside-out pharmacology of nicotine and nicotinic ligands
(1) Nicotine permeates lung epithelium, blood brain barrier and permeates cell membranes 
to enter intracellular organelles. (2) Nicotine enhances maturation of pentameric AChRs, 
increasing assembly in the ER (Kuryatov et al., 2005; Sallette et al., 2005). (3) ER retention 
is necessary for upregulation (Henderson et al., 2014; Srinivasan et al., 2011). (4) Cycling 
between the Golgi and ER is necessary for upregulation (Henderson et al., 2014). (5) 
Nicotinic ligands change the area of the peripheral ER (Henderson et al., 2014; Srinivasan et 
al., 2011). (6) The changes in AChR stoichiometry have occurred by the time AChRs have 
reached the Golgi (Henderson et al., 2014; Srinivasan et al., 2011). (7) Nicotine enhances 
the PM insertion rate of vesicles carrying α4β2 and α6β2β3 AChRs (Henderson et al., 2014; 
Richards et al., 2011). (8) Nicotinic ligands have differential effects on PM stoichiometry 
(Henderson et al., 2014; Nichols et al., 2014; Richards et al., 2012; Richards et al., 2011; 
Srinivasan et al., 2011; Srinivasan et al., 2012). (9) Nicotine and cytisine upregulate α4β2 
and α6β2β3 AChRs at concentrations that activate ≤0.4% of PM AChRs (Henderson et al., 
2014; Richards et al., 2012; Richards et al., 2011; Srinivasan et al., 2011). (10) Quaternary 
ammonium nicotinic ligands that permeate membranes poorly upregulate AChRs more 
slowly than nicotine and other tertiary ammonium ligands (Kuryatov et al., 2005). (11) 
Nicotine increases the number of trans-Golgi network bodies (Henderson et al., 2014; 
Srinivasan et al., 2011). (12) Nicotine enhances α4β2 AChR glycosylation. (13) β2 AChR 
subunit mutations that enhance ER exit change stoichiometry, similar to nicotine (Srinivasan 
et al., 2011). (14) Blocking proteasome activity upregulates AChRs. (15) Nicotine enhances 
the number of ER exit sites (Henderson et al., 2014; Srinivasan et al., 2011). (16) ER exit 
sites are increased by β2 AChR subunit M3-M4 loop mutations that introduce ER exit motifs 
(Srinivasan et al., 2011). (17) ER exit sites are increased by β2 AChR subunit M3-M4 loop 
mutations that eliminate ER retention motifs (Srinivasan et al., 2011). (18) Nicotinic ligands 
decrease ATF6 translocation to the nucleus (Srinivasan et al., 2012). (19) Nicotinic ligands 
decrease eIF2α phosphorylation (Srinivasan et al., 2012). (20) Nicotinic ligands reduce ER 
stress at concentrations that activate ≤0.4% of PM α4β2 AChRs. Brown font denotes events 
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involved with upregulation of PM AChRs; Blue font denotes events involved with 
upregulation and the reduced unfolded protein response.
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